Migränerton

Paracetamol, the active ingredient in Migränerton, is a Analgesic and Antiemetic combination presented as an oral tablet for oral use. It treats migraine attacks and associated nausea in adults.

GNH USA supplies Migränerton as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Migränerton is used in the management of migraine and related symptoms, acting on both pain pathways and gastrointestinal motility. - Migraine attacks: provides relief of headache pain and associated photophobia or phonophobia. - Acute headache: reduces intensity of sudden severe headaches. - Nausea and vomiting associated with migraine: alleviates gastrointestinal distress and improves tolerability of oral analgesics.

Common Side Effects: - Drowsiness: mild sedation may occur. - Dry mouth: reduced salivation. - Dizziness: transient light‑headedness. - Constipation: slowed bowel movements. - Abdominal discomfort: mild stomach upset. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Extrapyramidal reactions: muscle rigidity or involuntary movements. - Neuroleptic malignant syndrome: rare but life‑threatening hyperthermia. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Liver injury: risk with excessive paracetamol exposure. - Blood dyscrasias: uncommon hematologic abnormalities. - Seizures: rare central nervous system events.

Before using Migränerton, consider the following precautions. - Liver function assessment: avoid in patients with severe hepatic impairment. - Renal function monitoring: use cautiously in renal disease. - Hypersensitivity: discontinue if allergic reactions develop. - Extrapyramidal symptoms: monitor for movement disorders, especially with prolonged use. - Medical supervision: only use under prescriber direction. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Migränerton may interact with several medicines; awareness helps prevent adverse outcomes. Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Other dopamine antagonists: increased extrapyramidal risk. - High‑dose paracetamol products: cumulative hepatotoxicity. - Warfarin: enhanced anticoagulant effect, monitor INR. Moderate Interactions (Monitor Closely): - CYP450 substrates (e.g., phenytoin): possible altered metabolism. - CNS depressants (e.g., benzodiazepines): additive sedation. - Anticholinergic agents: may exacerbate dry mouth. - Diuretics: monitor electrolyte balance.